Pirfenidone: Anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients

European Journal of Pharmacology

Volumn 536, Issue 3, 2006, Pages 219-222

  Dosanjh, Amrita ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic rejection; Pirfenidone; Transplantation

Indexed keywords

ANTIFIBROTIC AGENT; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYTOKINE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; PIRFENIDONE; PLACEBO; RAPAMYCIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALLOTRANSPLANTATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRONCHIOLITIS OBLITERANS; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; DIZZINESS; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; FIBROSIS; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HUMAN; LIPID PEROXIDATION; LUNG FIBROSIS; LUNG GRAFT REJECTION; MULTIPLE SCLEROSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; OCULAR ALBINISM; ORGAN TRANSPLANTATION; PHOTOSENSITIVITY; PRIORITY JOURNAL; REVIEW; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRONCHIOLITIS OBLITERANS; HUMANS; LUNG TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PYRIDONES; TRANSPLANTATION, HOMOLOGOUS;

EID: 33646055456     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.03.007     Document Type: Review

References (21)

1. Azuma A., Nukiwa T., Tsuboi E., Suga M., Abe S., Nakata K., Taguchi Y., Nagai S., Itoh H., Ohi M., Sato A., and Kudoh S. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. AJRCCM 171 (2005) 1040-1047
2. Bergmann M., Tiroke A., Schafer H., Barth J., and Haverich A. Gene expression of profibrotic mediators in bronchiolitis obliterans syndrome after lung transplantation. Scand. Cardiovasc. J. 32 (1998) 97-103
3. Brook N.R., Waller J.R., Bicknell G.R., and Nicholson M.L. The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model. Transplant. Proc. 3 (2005) 130-133
4. Brook N.R., Waller J.R., Bicknell G.R., and Nicholson M.L. The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity. J. Surg. Res. 125 (2005) 137-143
5. Dosanjh A.K., Wan B., Throndset W., Sherwood S., and Morris R.E. Pirfenidone: a novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis. Transplant. Proc. 30 (1998) 1910-1911
6. Dosanjh A., Ikonen T., Wan B., and Morris R.E. Pirfenidone: a novel anti-fibrotic agent and progressive chronic allograft rejection. Pulm. Pharmacol. Ther. 15 (2002) 433-437
7. Gahl W.A., Brantly M., Troendle J., Avila N.A., Padua A., Montalvo C., Cardona H., Calis K.A., and Gochuico B. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol. Genet. Metab. 76 (2002) 234-242
8. Giri S.N., Leonard S., Shi X., Margolin S.B., and Vallyathan V. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J. Environ. Pathol. Toxicol. Oncol. 18 (1999) 169-177
9. Kaneko M., Inoue H., Nakazawa R., Azuma N., Suzuki M., Yamauchi S., Margolin S.B., Tsubota K., and Saito I. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin. Exp. Immunol. 113 (1998) 727-736
10. Liu H., Drew P., Cheng Y., and Visner G.A. Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model. J. Thorac. Cardiovasc. Surg. 130 (2005) 852-858
11. Liu H., Drew P., Gaugler A.C., Cheng Y., and Visner G.A. Pirfenidone inhibits lung allograft fibrosis through l-arginine-arginase pathway. Am. J. Transplant. 5 (2005) 1256-1263
12. McKane B.W., Fernandez F., Narayanan K., Marshbank S., Margolin S.B., Jendrisak M., and Mohanakumar T. Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model. Transplantation 77 (2004) 664-669
13. Nakazato H., Oku H., Yamane S., Tsuruta Y., and Suzuki R. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur. J. Pharmacol. 446 (2002) 177-185
14. Raghu G., Johnson W.C., Lockhart D., and Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. AJRCCM 159 (1999) 1061-1069
15. Reichenspurner H., Girgis R.E., Robbins R.C., Conte J.V., Nair R.V., Valentine V., Berry G.J., Morris R.E., Theodore J., and Reitz B.A. Obliterative bronchiolitis after lung and heart-lung transplantation. Ann. Thorac Surg. 60 (1995) 1845-1853
16. Shihab F.S., Bennett W.M., Yi H., and Andoh T.F. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am. J. Transplant. 2 (2002) 111-119
17. Shihab F.S., Bennett W.M., Yi H., and Andoh T.F. Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity. Transplantation 79 (2005) 419-426
18. To Y., Sano Y., Sekiya T., Ogawa C., Otomo M., Suzuki N., Arai Y., Isogane N., and Ito K. Successful treatment of steroid-resistant bronchiolitis obliterans-organizing pneumonia with orally administered cyclosporin and pirfenidone. Nihon Kokyuki Gakkai zasshi 38 (2000) 24-29
19. Trulock E.P., Edwards L.B., Taylor D.O., Boucek M.M., Keck B.M., and Hertz M.I. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report-2005. J. Heart Lung Transplant. 24 (2005) 956-967
20. Walker J.E., and Margolin S.B. Pirfenidone for chronic progressive multiple sclerosis. Mult. Scler. 7 5 (2001) 305-312
21. Zhou H., Latham C.W., Zander D.S., Margolin S.B., and Visner G.A. Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. J. Heart Lung Transplant. 24 (2005) 1577-1585